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ABSTRAK
Cytomegalovirus (CMV) retinitis merupakan penyakit yang berlaku pada pesakit yang 
menghidapi Human Immunodeficiency Virus (HIV) terutamanya. Ia juga dilaporkan 
pada pesakit tanpa HIV, contohnya pesakit yang menghidapi gangguan autoimun 
yang memerlukan immunosuppresif, pesakit menjalani pemindahan organ atau 
sumsum tulang, pesakit kanser darah atau payudara yang menerima kemoterapi, 
penyakit mata berikutan suntikan kortikosteroid intraokular atau periokular, kencing 
manis dan Good sindrom. Walau bagaimanapun, kes CMV retinitis dalam pesakit 
yang menghidapi dermatomyositis dan kanser pada masa yang sama tidak pernah 
dilaporkan sebelum ini. Ia juga tidak dilaporkan dalam kanser selain kanser darah 
atau payudara, atau pesakit kanser sebelum menerima rawatan kemoterapi. Kami 
melaporkan kes CMV retinitis dalam seorang wanita tanpa HIV berusia 40 tahun 
yang menghidapi dermatomyositis dan kanser paru-paru, di mana CMV retinitisnya 
kembali apabila immunosuppresif dimula semula. Kedua-dua episod CMV retinitis 
telah berjaya dirawat selepas mengambil kira keadaan keimunannya.
Kata kunci: cytomegalovirus retinitis, dermatomyositis, kanser paru-paru
ABSTRACT
Cytomegalovirus (CMV) retinitis occurs predominantly in Human Immunodeficiency 
Virus (HIV) -infected patients. It was also reported in HIV-seronegative patients 
with systemic autoimmune disorder requiring systemic immunosuppression, organ 
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malignancy including ovarian, lung, 
breast, pancreatic, stomach, colorectal, 
nasopharyngeal cancers, and non-
Hodgkin lymphoma (Olazagasti et al. 
2015). The reported incidence of cancer 
associated with dermatomyositis varies 
from less than 7% to over 30% (Di 
Rollo et al. 2014).
 CMV retinitis in patients with i) 
concurrent dermatomyositis and 
malignancy, ii) cancer other than 
haematological or breast malignancy, 
or iii) cancer prior to chemotherapy 
has not been previously reported. We 
describe a case of CMV retinitis in a HIV-
seronegative patient diagnosed with 
dermatomyositis and lung malignancy. 
CASE REPORT
A 40-year-old woman with 
dermatomyositis complained of right 
eye blurred vision and floaters for three 
weeks. She was on oral Azathioprine 
100mg OD, oral prednisolone 15mg OD 
and hydroxychloroquine 300mg OD for 
13 months. Examination revealed right 
vision of 6/18 with no relative afferent 
or bone marrow transplantation, haematological or breast malignancy receiving 
chemotherapy, ocular diseases following intraocular or periocular corticosteroid 
injection, diabetes mellitus and Good syndrome. However, CMV retinitis in patients 
with concurrent dermatomyositis and malignancy has not been previously reported. 
It has not been reported in cancer other than haematological or breast malignancy, 
or in cancer patient prior to chemotherapy. We report a case of 40-year-old 
HIV-seronegative woman with underlying dermatomyositis and lung malignancy 
who developed right CMV retinitis which relapsed after recommencement of 
immunosuppressant. Both episodes of CMV retinitis were successfully treated after 
taken her immunocompromised state into consideration.
Key-words: cytomegalovirus retinitis, dermatomyositis, lung neoplasms
INTRODUCTION
Cytomegalovirus (CMV) retinitis 
is an opportunistic eye infection 
characterized by dense, white confluent 
opacification of the retina along the 
vessels with retinal haemorrhage and 
vascular sheathing. It predominantly 
occurs in patients with acquired 
immunodeficiency syndrome (AIDS) 
with CD4 cell counts less than 50 
cells/mm3. It has also been reported in 
Human Immunodeficiency Virus (HIV)-
seronegative patients with systemic 
autoimmune disorder requiring 
systemic immunosuppression, organ 
or bone marrow transplantation; 
haematological or breast malignancy 
receiving chemotherapy; ocular 
diseases following intraocular or 
periocular corticosteroid injection; 
diabetes mellitus and Good syndrome 
(Kim et al. 2007; Han et al. 2015; 
Downes et al. 2016). 
 Dermatomyositis is an idiopathic 
inflammatory myopathy with 
characteristic skin manifestations. 
It has a strong association with 
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pupillary defect. Anterior segment 
examination was unremarkable. Right 
fundus showed haemorrhagic retinitis 
along inferotemporal vessel with 
presence of vitreous condensation 
(Figure 1). CMV retinitis was confirmed 
by positive polymerase chain reaction 
(PCR) from vitreous fluid. Vitreous PCR 
for Herpes simplex 1 & 2 and Varicella 
zoster were not detected. HIV serology 
was negative and she was not diabetic. 
Her absolute lymphocyte count was 
0.67 x 109/L. The patient was started 
on daily intravenous Ganciclovir 5mg/
kg BD for two weeks and biweekly 
intravitreal Ganciclovir 2mg/0.1 ml. 
Azathioprine was withheld in view 
that the retinitis was most probably 
due to immunosuppressive state. Oral 
prednisolone was reduced to 10mg 
OD. Her vision improved to 6/9 and 
lesions resolved (Figure 2). Absolute 
neutrophil count at the end of antiviral 
therapy was 2.60 x 109/L while absolute 
lymphocyte count increased to 1.10 x 
109/L. Due to financial reasons and 
non-availability of oral valganciclovir in 
our hospital, patient was not able to be 
started on the maintenance Ganciclovir, 
nevertheless intravitreal Ganciclovir 
was continuously given as biweekly till 
the lesion become scarred. At week 3 
when the retinitis became inactive, the 
intravitreal Ganciclovir was stopped. 
 After a month without Azathioprine, 
her systemic disease flared up. She 
had severe generalized skin itchiness 
and redness, Heliotrope rash, Gottron 
papules and proximal myopathy. 
Oral Azathioprine 50mg OD was 
recommenced and skin condition was 
controlled. 
 A month later, right eye CMV 
retinitis was reactivated with the lesion 
approaching the macula (Figure 3). 
Azathioprine was withheld again. She 
was treated with biweekly intravitreal 
Ganciclovir for four weeks. The 
retinitis subsequently resolved with 6/9 
vision (Figure 4). Skin condition was 
otherwise status quo. The patient opted 
to discontinue azathioprine in fear that 
the retinitis would recur. Contralateral 
eye was not involved throughout the 
follow-up. 
 Three months later, the patient 
developed pathological lumbar fracture. 
A magnetic resonance imaging of spine 
Figure 1: Right fundus examination revealed 
hemorrhagic retinitis along the inferotemporal 
vessel and vitreous condensation along 
superotemporal vessel
Figure 2: Resolving retinal lesion at one month 
following treatment
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incidentally revealed a lung mass. The 
patient refused for lung biopsy and 
was diagnosed with presumed stage IV 
lung malignancy with bone metastasis. 
She declined chemotherapy and 
immunosuppressant; and defaulted 
all follow up. According to the phone 
interview, her ocular symptoms did 
not recur. She passed away ten months 
after the diagnosis of lung malignancy.
DISCUSSION
CMV retinitis was well recognized in 
patients receiving immunosuppressant. 
This is evidenced in a study, where 
CMV antigenemia was detected in 60% 
of patients taking prednisolone of more 
than 30 mg/day, suggesting that CMV 
infection occurs with high frequency 
during immunosuppressive therapy 
(Yoshihara et al. 1999). In patients with 
inflammatory connective tissue disease, 
CMV DNA which was previously not 
present prior to immunosuppressive 
therapy, was detected in peripheral 
blood leukocytes in 70% of patients 
after receiving immunosuppressant. 
This signifies a high risk of CMV 
reactivation in patients requiring 
immunosuppression (Mori et al. 
2004). In this case, we believed that 
recommencement of Azathioprine after 
the first course of systemic Ganciclovir 
promoted the reactivation of CMV 
infection. 
 Another reason contributing the 
recurrence was the patient might already 
have lung malignancy during the event 
of CMV retinitis. The chronicity of the 
advance malignancy as evident by bone 
metastasis could further suppress the 
patient’s immune state. To date, CMV 
retinitis was reported in patients with 
leukemia, lymphoma, and multiple 
myeloma during or after receiving 
maintenance therapy (Han et al. 2015; 
Downes et al. 2016). Only one case was 
reported in breast malignancy (Downes 
et al. 2016). However, incidence of 
CMV retinitis in lung malignancy, or in 
malignancy prior to chemotherapy has 
not been previously reported. 
 Although dermatomyositis itself can 
compromise host immunity, it is less 
likely in this case because the disease 
Figure 3: Reactivation of right eye CMV retinitis 
(arrow) that was approaching the macula. 
Artifacts were marked with asterisk (*)
Figure 4: Resolution of recurrent retinitis 
following four weeks of intravitreal Ganciclovir
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activity of dermatomyositis was not 
significant at the time of diagnosis of 
both CMV retinitis and its reactivation 
(Ku et al. 1999). CMV retinitis did not 
recur despite the patient was no longer 
on immunosuppressant thereafter. 
 This patient was given an initial 
‘induction’ course of systemic 
Ganciclovir for 14 days to inactivate 
CMV while preventing systemic spread 
and further enlargement of retinal 
lesions. Ideally, maintenance treatment 
with oral Valganciclovir is the best option 
following induction course. Moreover 
it would be expected for the patient to 
develop recurrent CMV retinitis when 
azathioprine was reinstituted. However, 
oral Valganciclovir is too costly, 
therefore she chose to have intravitreal 
Ganciclovir whenever disease gets 
reactivated. Another reason intravitreal 
Ganciclovir chosen as alternate 
treatment modality for reactivation was 
to avoid any possible systemic effect it 
may have on the bone marrow. This is 
because systemic Ganciclovir therapy 
can cause myelosuppression, hence an 
already compromised immune system 
may be further suppressed (Langner-
Wegscheider et al. 2010). Fortunately, 
our patient showed a quick response to 
Ganciclovir in both events. In cases of 
resistance, other choices of treatment 
include Foscarnet and Cidofovir, 
however all of which are virustatic (Au 
Eong et al. 1999).
 Visual outcome in this patient was 
promising as the CMV retinitis was 
detected early. Although maintenance 
treatment could not be given, close 
monitoring and intensive intravitreal 
injection were able to secure her 
vision. At times, vision remains the 
main concern of the patient, as the 
patient was willing to discontinue 
Azathioprine for the fear of recurrence 
of CMV retinitis. 
CONCLUSION
It is a great challenge for both 
ophthalmologists and rheumatologists 
to treat concurrent CMV retinitis and 
dermatomyositis. As the damage to 
the retina caused by CMV retinitis is 
permanent, early detection of the disease 
remains critical in preserving the vision. 
Patients on immunosuppressant have to 
be warned of risk of CMV retinitis and 
should be educated about reporting 
visual disturbances (floaters, blurred 
vision, or scotoma). Close follow-
up by ophthalmologists is at utmost 
importance because CMV retinitis 
usually occurs in periphery retina and 
patients might remain asymptomatic. 
Co-management with rheumatologists 
is essential for monitoring of the 
systemic disease, adjustment of 
immunosuppressant and malignancy 
screening in dermatomyositis. 
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